Even as millions of older adults clamor for drugs such as Ozempic and Wegovy, monthly use of the medications known as GLP-1 receptor agonists soared ... “These medications work from a weight ...

As the body of research expands on the potential of glucagon-like peptide-1 receptor agonists to address various health ...

The drug semaglutide has been linked to a lower risk of alcoholism before, but now we have strong evidence that it really does help curb drinking ...

Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...

Now, the growing buzz around the use of GLP-1 medications like Ozempic to treat alcohol use disorder finally has new clinical ...

If the CMS rule to cover obesity medications is finalized, coverage will increase by other insurers, experts predicted. HHS ...

Phase 2 obesity co-administration study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatide Database lock completed Topline data readout ...

A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.

In 2022, when the surge in popularity of the GLP-1 class of weight loss and diabetes drugs really began, stories of surprise ...

Researchers have pointed out on the limited data on the research and have suggested to continue using the three approved ...